Biopharmazeutika Werden

About Bio pharmazeutika werden

The latest generation of biotechnological drugs that are usually derived from living cells, are changing the way that medical conditions are treated. In contrast to traditional small molecule medicines that use chemicals, bio pharmazeutika are produced from a wide range of biological compounds and are designed to treat a wide range of diseases that have not been adequately addressed by the current treatments that are based on small molecules.

Biopharmazeutika werden are produced using gentechnische production (GTP) from in cultured bacteria, mammalian cells such as the popular CHO-Zellen, or even plants, which can be cultivated using plant biotechnology (Pflanzenbiotechnologie). Contrary to conventional pharmaceuticals that are created in the lab using chemical methods and processes, all biopharmazeutika are made by living organisms and therefore must be distinguished by their individual atom-by-atom structure.

Due to their complexity bio pharmazeutika are not able to be replicated exactly by scientists. They are referred to as biosimilars, not generics. After the patent protection for the original medication expires, companies can create and sell their own versions, provided they meet certain legal requirements. They are known as Biosimilar Guidelines.

Biopharmazeutika can be taken directly or as part of the manufacturing of a range of therapeutic devices, including peptides and polysaccharides. During the downstream processing of Biopharmazeutika these substances are recombined in order to form complex biological drugs. Examples of biopharmazeutika recombinant are insulin, interleukin and monoclonal antibodies.

Leave a Reply

Your email address will not be published. Required fields are marked *